1. Age: 18-75 years old, no limitation in gender; 
2. Left ventricular ejection fraction (LVEF) ≤ 40% (ECHO); 
3. Patients with chronic heart failure (NYHA class II or III); 
4. In the past one month, the clinical condition (including history, clinical symptoms and signs) was relatively stable; 
5. Patients on standard treatment of chronic heart failure at the target dose or maximum tolerance dose for over 1 month ,or unchanged dose in last 1 month; 
6. Understand and sign the informed consent form; 

NCT01214096_inc_T1
Value
18-75 years
NCT01214096_inc_T2
Person
Age
NCT01214096_inc_T3
Measurement
Left ventricular ejection fraction (LVEF)
NCT01214096_inc_T4
Value
≤ 40%
NCT01214096_inc_T5
Procedure
ECHO
NCT01214096_inc_T6
Condition
chronic heart failure
NCT01214096_inc_T7
Measurement
NYHA
NCT01214096_inc_T8
Value
class II or III
NCT01214096_inc_T9
Temporal
In the past one month
NCT01214096_inc_T10
Observation
history
NCT01214096_inc_T11
Condition
clinical symptoms
NCT01214096_inc_T12
Condition
clinical signs
NCT01214096_inc_T13
Qualifier
relatively stable
NCT01214096_inc_T14
Scope
history, clinical symptoms and signs
NCT01214096_inc_T15
Condition
chronic heart failure
NCT01214096_inc_T16
Procedure
treatment of chronic heart failure
NCT01214096_inc_T17
Observation
maximum tolerance dose
NCT01214096_inc_T18
Observation
target dose
NCT01214096_inc_T19
Temporal
for over 1 month
NCT01214096_inc_T20
Temporal
in last 1 month
NCT01214096_inc_T21
Observation
unchanged dose
NCT01214096_inc_T22
Scope
target dose or maximum tolerance dose
NCT01214096_inc_T23
Scope
target dose or maximum tolerance dose for over 1 month ,or unchanged dose in last 1 month